Content Detail

• Content META

  Title	Ensuring Ethics in AI-Driven Drug Safety
  ID	5181171
  External ID	7397037527
  Author	Unknown
  Published Date	Dec. 16, 2024, 11:52 p.m.
  Summary	Ashish Jain, Senior Director of Pharmacovigilance and Risk Management at Curis Inc. Ashish Jain is Senior Director of Pharmacovigilance and Risk Management at Curis Inc., with over 12 years of experie
  Tags	None
  URL	https://www.pharmafocusasia.com/interviews/ashish-jain
  Sentiment	Negative: 0.01288    Neutral: 0.83154    Positive: 0.15558
  Relevance	0.00417

• Content Details

  Content ID	3117164
  Key	a0b744ab-b89d-4053-bd3a-cccd15fb1e9f
  Content	Ashish Jain, Senior Director of Pharmacovigilance and Risk Management at Curis Inc. Ashish Jain is Senior Director of Pharmacovigilance and Risk Management at Curis Inc., with over 12 years of experience in drug safety. He is also leading the Innovation Working Group at the North American Society of Pharmacovigilance (NASoP), his expertise in combining technological innovation with patient safety makes him uniquely qualified to address the ethical challenges of AI implementation in pharmacovigilance. His article focuses on developing frameworks for ethical AI implementation in healthcare. Q: Your recent paper in Drug Safety Journal addresses the ethical implementation of AI in pharmacovigilance. What motivated this and why is it particularly relevant now? A: The field of healthcare is going through a paradigm shift, and artificial intelligence is at the forefront of this change especially in drug safety surveillance. While the potential benefits are enormous, we identified a critical gap in ethical frameworks governing this integration. Our research was motivated by the urgent need to ensure patient safety and privacy are not compromised in the rush to adopt these powerful technologies. What makes this particularly relevant now is the rapid acceleration of AI adoption in healthcare. We see increasingly sophisticated AI systems being deployed for adverse event detection and risk assessment, but without comprehensive ethical guidelines, we risk creating systems that could perpetuate biases or compromise patient privacy. Our paper addresses these challenges head-on, providing practical solutions for organisations implementing AI in pharmacovigilance. Q: Your paper introduces a novel cognitive framework for ethical AI implementation. Could you elaborate on its key components and what makes it unique? A: Our framework is distinctive because it addresses the entire lifecycle of AI in pharmacovigilance, from initial data collection through to regulatory reporting. What makes it particularly innovative is its practical, implementable approach to ethical considerations. The framework consists of several interconnected components. First, we address data privacy and security through privacy-preserving techniques like differential privacy and federated learning. Second, we tackle algorithmic bias through comprehensive guidelines for diverse data collection and regular bias testing. Third, we emphasize transparency and explainability in AI decision-making through techniques like SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations). Most importantly, we have designed the framework to be adaptable and scalable, recognising that both AI technology and ethical considerations will continue to evolve. Q: How does your research address the challenge of balancing innovation with ethical responsibility? A: This is perhaps one of the most crucial aspects of our work. We recognise that innovation in AI can dramatically improve drug safety monitoring, but it shouldn't come at the cost of ethical considerations. Our research provides specific guidelines for maintaining this balance. For instance, we propose a multi-stakeholder approach where AI developers, healthcare providers, and regulatory experts collaborate throughout the development process. We have outlined specific checkpoints where ethical considerations must be evaluated, without impeding technological progress. We have also introduced the concept of "ethical roadmap" in AI development for pharmacovigilance. This means incorporating ethical considerations from the earliest stages of system development, rather than treating them as compliance requirements to be addressed later. Q: Your paper emphasizes the importance of transparency in AI decision-making. How do you propose achieving this in practice? A: Transparency is indeed crucial, particularly in healthcare where AI decisions can directly impact patient safety. Our paper proposes several practical approaches to achieve this. First, we advocate for explainable AI (XAI) techniques that can provide clear rationales for AI decisions in drug safety monitoring. We have detailed specific methodologies for maintaining transparency at different levels - from algorithm development to result interpretation. This includes maintaining comprehensive documentation of training data sources, regular audits of AI decisions, and creating interpretable outputs that healthcare professionals can easily understand and validate. Importantly, we have also addressed how to maintain transparency without compromising system performance or intellectual property rights, which has been a significant challenge in the field. Q: Your paper discusses data privacy challenges in AI-driven pharmacovigilance. How do you propose balancing data access needs with privacy protection? A: This is one of the most nuanced challenges in implementing AI for drug safety. Our research proposes a multi-layered approach to privacy protection while maintaining data utility. We have outlined specific technical solutions like federated learning, where AI models can learn from distributed datasets without centralising sensitive patient information. This allows organisations to benefit from large-scale data analysis while keeping patient data secure within their original institutions. We have also developed guidelines for implementing privacy-preserving techniques such as differential privacy, which adds controlled noise to datasets to protect individual privacy while maintaining statistical validity. The key innovation here is finding the right balance - ensuring enough data access for AI systems to function effectively while maintaining robust privacy protections. Q: Could you elaborate on how your framework addresses the challenge of AI bias in safety signal detection? A: Our research identified that bias in safety signal detection could have serious consequences for patient safety. We developed a comprehensive approach that addresses bias at multiple levels. First, at the data collection level, we recommend specific strategies for ensuring diverse representation in training datasets, including demographic, geographic, and clinical diversity. We have also introduced novel validation protocols that specifically test for bias in signal detection algorithms. This includes regular equity audits and the use of synthetic datasets to test system performance across different population groups. What makes our approach unique is that it combines technical solutions with procedural safeguards, ensuring that bias mitigation is an ongoing process rather than a one-time check. Q: How does your research address the integration of human expertise with AI capabilities in pharmacovigilance? A: This is a critical aspect of our framework that sets it apart from previous work. Rather than viewing AI as a replacement for human expertise, we have developed specific guidelines for human-AI collaboration in pharmacovigilance. Our research shows that optimal outcomes are achieved when AI systems augment rather than replace human decision-making. We have outlined specific roles where human oversight is crucial, particularly in interpreting complex safety signals and making final decisions about risk management. The framework includes detailed protocols for maintaining human expertise in the loop while leveraging AI's capabilities for data processing and pattern recognition. This balanced approach ensures that we benefit from AI's analytical power while maintaining the critical thinking and contextual understanding that human experts provide. Q: Could you discuss some of the specific ethical challenges you've identified in AI-driven pharmacovigilance and how your framework addresses them? A: Our research identified several critical ethical challenges. The first is data privacy - medical data is highly sensitive, and AI systems require large amounts of it. We have proposed specific technical solutions like homomorphic encryption and secure multi-party computation to protect patient privacy while enabling effective AI analysis. Another significant challenge is algorithmic bias. AI systems can inadvertently perpetuate or amplify existing healthcare disparities if not properly designed. Our framework includes comprehensive guidelines for bias testing and mitigation, including recommendations for diverse data collection and regular equity audits. We also addressed the challenge of responsibility and accountability in AI-driven decisions. Our framework clearly delineates roles and responsibilities among different stakeholders, ensuring clear accountability while promoting collaborative decision-making. Q: How do you see your work influencing the future of AI implementation in healthcare? A: Our research is already influencing how organisations approach AI implementation in pharmacovigilance. We are seeing companies adopt our ethical framework as part of their AI development process, and regulatory bodies are considering similar principles in their guidelines. Looking ahead, I believe our work will contribute to establishing industry standards for ethical AI in healthcare. The framework we have developed is adaptable to other healthcare domains beyond pharmacovigilance, potentially improving patient safety across multiple areas. One of the most significant potential impacts is in promoting responsible innovation. By providing clear guidelines for ethical AI implementation, we are helping organisations navigate the complex landscape of AI in healthcare while maintaining high ethical standards. Q: What advice would you give to organisations looking to implement AI in their pharmacovigilance systems based on your research? A: The key message from our research is that ethical considerations should be integrated from the very beginning of AI implementation. Organisations should start by establishing clear ethical guidelines and ensuring they have the right expertise - not just in AI technology, but also in ethics and healthcare regulations. We recommend following our framework's step-by-step approach, beginning with a thorough assessment of data privacy measures and bias mitigation strategies. It's also crucial to establish robust governance structures and maintain regular ethical audits of AI systems. Most importantly, organisations should foster a culture of ethical awareness and continuous learning. AI technology is evolving rapidly, and staying current with ethical considerations is just as important as keeping up with technological advances.
  Content Reference URL	None

• Publisher

  Publisher Name	Pharma Focus Asia
  Publisher URL	https://www.pharmafocusasia.com/
  Description	None
  Trust Flow Score	27
  Citation Flow Score	35

• Data Source

  Data Source Name	Quantexa News
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10